Listen
MEKTOVI (binimetinib) - Melanoma
Opinions on drugs -
Posted on
Nov 27 2024
Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement in the treatment of adult patients with unresectable or
metastatic melanoma with a BRAF V600 mutation in combination with encorafenib.
No clinical added value of the MEKTOVI 45 mg film-coated tablet form compared to the proprietary medicinal product containing binimetinib already available.
Clinical Benefit
| Moderate |
The Committee considers that the clinical benefit of the BRAFTOVI/MEKTOVI 45 mg film-coated tablet (encorafenib/binimetinib) combination is moderate in the MA indication. |
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the form already listed. |
Documents
English version
Contact Us
Évaluation des médicaments
